3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
6
Prostatic Neoplasms
5
Neoplasms
3
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Pancreatic Neoplasms
2
Glioblastoma
2
Urogenital Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Squamous Cell
1
Metastatic Castration-Resistant Prostate Cancer
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Hormone Receptor Positive Breast Cancer
1
Head and Neck Neoplasms
1
Glioma
1
Ependymoma
1
Interventions
sapanisertib
1
onvansertib
1
enzalutamide
1
abiraterone
1
abemaciclib
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Castration-Resistant Prostate Cancer
×
abemaciclib
×
Clear all
NCT04408924
2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2
Completed
44 enrolled
21 charts